Kalaris Therapeutics KLRS
NASDAQ KLRS
$1.90 +0.03 (+1.60%)
At close: Nov 11, 2026 · 4:00 PM EST

Kalaris Therapeutics (KLRS) Return on Capital Employed [ROCE] (2020 - 2026)

Updated

Kalaris Therapeutics (KLRS) recorded Return on Capital Employed [ROCE] of -49.79% in Q2 2026, up 25.05 percentage points from -74.84% a year earlier but down 5.56 percentage points from the prior quarter.

Analysis

Kalaris Therapeutics (KLRS) Return on Capital Employed [ROCE] (2020 - 2026) Analysis & Trends

For FY2025, Kalaris Therapeutics reported Return on Capital Employed [ROCE] of -85.10%, down 14.98 percentage points from FY2024.

  • Annual Return on Capital Employed [ROCE] has a five-year change of -55.73 percentage points (FY2020 to FY2025).
  • Across earlier years, Return on Capital Employed [ROCE] came in at -70.12% in FY2024 (+27.12 pp), -97.24% in FY2023 (-30.76 pp), -66.49% in FY2022 (-8.10 pp) and -58.39% in FY2021 (-29.02 pp).
  • Quarterly Return on Capital Employed [ROCE] has ranged from -130.49% in Q4 2024 to -44.23% in Q1 2026 over the past five years.
  • On a year-over-year basis, Return on Capital Employed [ROCE] has increased for five consecutive quarters, with an average year-over-year change of +21.23 percentage points over the last eight quarters.
  • Peak year-over-year performance for Return on Capital Employed [ROCE] in the last five years was a gain of 81.12 percentage points in Q1 2026, against a drop of 60.53 percentage points in Q2 2022 at the low end.
  • Per Business Quant, the preceding three quarters came in at -44.23% (Q1 2026), -50.31% (Q4 2025) and -52.49% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 Kalaris Therapeutics 44.52 Mn -38.38 Mn - -54.61%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -54.61%
Jun 30, 2026 -49.79%
Mar 31, 2026 -44.23%
Dec 31, 2025 -50.31%
Sep 30, 2025 -52.49%
Jun 30, 2025 -74.84%
Mar 31, 2025 -125.35%
Dec 31, 2024 -130.49%
Sep 30, 2024 -85.37%
Jun 30, 2024 -85.88%
Mar 31, 2024 -99.64%
Dec 31, 2023 -104.56%
Sep 30, 2023 -76.55%
Jun 30, 2023 -74.71%
Mar 31, 2023 -72.68%
Dec 31, 2022 -65.58%
Sep 30, 2022 -82.50%
Jun 30, 2022 -97.51%
Mar 31, 2022 -75.83%
Dec 31, 2021 -64.40%
API Access

Kalaris Therapeutics Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=KLRS&period=max&api_key=YOUR_API_KEY